Gerald Coquillard1, Bibiana Palao, Bruce K Patterson. 1. Department of Pathology and Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA.
Abstract
OBJECTIVES: Current methods for HPV screening rely on the detection of L1 DNA from high risk genotypes (HRHPV). These assays have very high negative predictive values (~99%), however, the specificity and positive predictive value of HPV DNA tests for pre-cancerous and cancerous lesions (CIN 2+) is less than 50%. The purpose of this study was to compare HPV DNA with intracellular HPV E6, E7 mRNA quantification in an effort to improve the performance of cervical cancer screening. METHODS: Liquid-based cervical cytology specimens collected in either PreservCyt or SurePath were processed for routing cytology, HPV HRDNA detection by Hybrid Capture 2 and HPV E6, E7 mRNA quantification in cells using the same sample. We analyzed a total of 2049 samples including 73 with CIN 2, CIN 3, or squamous cell carcinoma by biopsy and 1694 samples from women with normal cytology. RESULTS: The positive predictive value of HPV E6, E7 mRNA quantification in cells for CIN2+ was 78% which was greater than HPV DNA alone (43%). The specificity of HPV E6, E7 mRNA quantification was 96% based on normal cytology compared to 82% for HC2 while the specificity of HPV E6, E7 mRNA quantification based on CIN 2- histology was 85% compared to 35% for HC2. CONCLUSIONS: With similar sensitivity and greater specificity/positive predictive value, HPV E6, E7 mRNA quantification in cells is an improvement over HPV DNA for cervical cancer screening.
OBJECTIVES: Current methods for HPV screening rely on the detection of L1 DNA from high risk genotypes (HRHPV). These assays have very high negative predictive values (~99%), however, the specificity and positive predictive value of HPV DNA tests for pre-cancerous and cancerous lesions (CIN 2+) is less than 50%. The purpose of this study was to compare HPV DNA with intracellular HPV E6, E7 mRNA quantification in an effort to improve the performance of cervical cancer screening. METHODS: Liquid-based cervical cytology specimens collected in either PreservCyt or SurePath were processed for routing cytology, HPV HRDNA detection by Hybrid Capture 2 and HPV E6, E7 mRNA quantification in cells using the same sample. We analyzed a total of 2049 samples including 73 with CIN 2, CIN 3, or squamous cell carcinoma by biopsy and 1694 samples from women with normal cytology. RESULTS: The positive predictive value of HPV E6, E7 mRNA quantification in cells for CIN2+ was 78% which was greater than HPV DNA alone (43%). The specificity of HPV E6, E7 mRNA quantification was 96% based on normal cytology compared to 82% for HC2 while the specificity of HPV E6, E7 mRNA quantification based on CIN 2- histology was 85% compared to 35% for HC2. CONCLUSIONS: With similar sensitivity and greater specificity/positive predictive value, HPV E6, E7 mRNA quantification in cells is an improvement over HPV DNA for cervical cancer screening.
Authors: Zhenping Shen; Xia Liu; Janice Morihara; Ayaka Hulbert; Laura A Koutsky; Nancy B Kiviat; Long Fu Xi Journal: Intervirology Date: 2016-01-28 Impact factor: 1.763
Authors: Abraham Pouliakis; Efrossyni Karakitsou; Charalampos Chrelias; Asimakis Pappas; Ioannis Panayiotides; George Valasoulis; Maria Kyrgiou; Evangelos Paraskevaidis; Petros Karakitsos Journal: Biomed Res Int Date: 2015-08-03 Impact factor: 3.411
Authors: Panagiotis Bountris; Maria Haritou; Abraham Pouliakis; Niki Margari; Maria Kyrgiou; Aris Spathis; Asimakis Pappas; Ioannis Panayiotides; Evangelos A Paraskevaidis; Petros Karakitsos; Dimitrios-Dionyssios Koutsouris Journal: Biomed Res Int Date: 2014-04-09 Impact factor: 3.411